Tetroxoprim

Tetroxoprim
Clinical data
ATC code	J01EE06 (WHO) (with sulfadiazine);
Identifiers
	IUPAC name 5-[3,5-Dimethoxy-4-(2-methoxyethoxy)benzyl]pyrimidine-2,4-diamine;
CAS Number	53808-87-0 ;
PubChem CID	65450;
ChemSpider	58910 ;
UNII	5R6712AY0K;
KEGG	D06097 ;
ChEMBL	ChEMBL32039 ;
CompTox Dashboard (EPA)	DTXSID80202085 ;
ECHA InfoCard	100.053.427
Chemical and physical data
Formula	C16H22N4O4
Molar mass	334.70 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COCCOC1=C(C=C(C=C1OC)CC2=CN=C(N=C2N)N)OC;
	InChI InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20) ; Key:WSWJIZXMAUYHOE-UHFFFAOYSA-N ;
(what is this?) (verify)

Tetroxoprim (INN) is a derivative of trimethoprim. It was first described in 1979.[1]

References

Aschhoff HS, Vergin H (November 1979). "Tetroxoprim—a new inhibitor of bacterial dihydrofolate reductase". J Antimicrob Chemother. 5 (B): 19–25. doi:10.1093/jac/5.supplement_b.19. PMID 43863.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.